Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11332)	8/17/1999 3:30:00 PM
From: Slugger	Respond to of 17367

George, Today's action is surprisingly strong considering the news. I had expected the stock to dip to 3 with a small bounce, but there appears to be good support around 4 1/2. We've now had approximately 10% of the outstanding stock traded today which means 10% of the shareholders are new and ready to hold on for the time being. I think what the market might be telling us is that, even if this Neuprex trial fails, there is a potential buyer of the company above $5/share. Or it might even be telling us that there's a better than even chance that this trial really was a success. Anyway, after watching the market this morning and much deliberation I've decided to hold my shares for the time being. I expect us to retest the 4 3/8 area tomorrow and then we'll do a little basing. With all the shares shaken out today I think it will take another bout of bad news to drive the price below 4. JMHO. All standard K disclaimers apply. Knock on wood... Hail Mary... Etc, etc. :-)

To: aknahow who wrote (11332)	8/17/1999 6:42:00 PM
From: William L. Molair II	Read Replies (1) \| Respond to of 17367

I spoke with Ellen this morning around 8AM EDT and discussed the following (none of these should be construed as direct quotes): 1.) Conference Call - you might get more participation if you announced the call a little further in advance and allowed more time in between your press release and the time in which the call begins. Ellen said essentially point taken. 2.) Were Sutro and CIBC on the call. Ellen said yes; but they didn't have any questions. In fact, they both issued research reaffirming their previous opinions on the company. 3.) After reading the press release and listening to the conference call - I made the conclusion that we are no better or worse (as far as mengiocoximia is concerned) than we were a week ago. Ellen agreed and suggested that we were actually slightly better. 4.) Asked about the Bloomberg piece. Ellen unequivocally stated that she was misquoted. I may have to retract the following statements in the future; but, I feel the need to say the following. 1.) I am really disappointed in how Xoma chose to release the Phase III info yesterday. The press release was poor and the conference call worse. I would have preferred a simple no comment than release the very small amount of information that we have received. Hopefully they have learned. 2.) I am also disappointed with some of the posts here on SI. I expect this sortof stuff on Yahoo. That's why I hang out here. Personal attacks on Ellen do not bring any value to this board. I have always found her to be very professional and look forward to being able to call her in the future. Who knows the inner workings at Xoma - maybe the CEO/CFO made the decisions on how to release the info. As far as the Bloomberg article is concerned - I think we all saw how misinformation can occur as CNBC gleamed its headlines from Bloomberg and further distorted the truth. 3.) I fully believe that CIBC and Sutro were buying stock this morning. Wish somebody could confirm this. 4.) Xoma did EXACTLY what Ellen said they would do in August. Release a very generic statement about the Phase III trial results. Anyone who purchased the stock expecting more needs to do a little more research before buying next time. 5.) I expect (better yet demand) full disclosure of the Phase III data in October after the FDA meeting.